People in the News: Megan Bailey, Fortunato Ron Rocca, Julien Bradley, More

Personal Genome Diagnostics has appointed Megan Bailey as chief commercial officer. Bailey joined the firm as VP of marketing in 2018. Prior to PGDx, Bailey spent more than 14 years at Roche in various sales and marketing roles, most recently as senior director of commercial operations.

---

Interpace Biosciences: Fortunato Ron Rocca, Felice Schnoll-Sussman, James Early, Fred Knechtel, Jeff Salzman

Interpace Biosciences has appointed Fortunato Ron Rocca as a class II director. Rocca will serve on the firm's board as a non-employee director. Concurrently with the appointment, Felice Schnoll-Sussman has resigned from Interpace Bio's board. Rocca currently serves as president and CEO of Exagen.

 

Interpace Bio also said that CFO and Treasurer James Early is retiring from the firm. Early will be replaced by Fred Knechtel, who previously served as CFO at Genewiz.

 

Interpace Bio has also appointed Jeff Salzman as VP of managed care and payor relations. Prior to Interpace Bio, Salzman held roles at Quest Diagnostics, Monogram Biosciences, Vermillion, and most recently at CareDx.

RedShift BioAnalytics (RedShiftBio) , a provider of analytical solutions for protein characterization in biotherapeutic development, has appointed Julien Bradley as CEO. Bradley most recently served as vice president of marketing, corporate development and strategy at Quanterix, where he also previously served as VP of marketing and sales operations. He has also held senior roles at Phosphorus, OvaScience, and Thermo Fisher Scientific.

---

For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.